InflaRx to develop izicopan in AAV

InflaRx (IFRX) announced that it intends to develop izicopan, an oral C5a receptor inhibitor, in AAV, a life-threatening kidney disorder. InflaRx is conducting Phase 2 planning for izicopan in AAV and is evaluating the feasibility of multiple development approaches, including the potential for an expedited path to the commercial market, in an effort to best address the evolving regulatory environment surrounding the currently approved comparator, avacopan. In addition, the company has announced its goal of establishing rapid proof of concept for izicopan across a broader range of complement-mediated life-threatening kidney diseases by conducting open-label studies that are expected to begin generating clinical data next year in certain indications. Toward these efforts, InflaRx anticipates conducting a pharmacokinetic bridging study in China this year.